The investigators induced renovascular hypertension (RVH) using a two-kidney, two-clip surgery in rats and then followed imaging and pathology. Approximately two-thirds of animals developed white matter hyperintensities that expanded between weeks 7 and 9 on T2-weighted MRI. Diffusion metrics changed alongside lesion growth: fractional anisotropy was reduced in affected regions, indicating microstructural disruption. Histologic analysis matched the imaging. The cohort showed frank demyelination, axonal loss, and a reduced number of mature oligodendrocytes within lesion zones. Glial activation co-occurred with those degenerative changes. Blood–brain barrier leakage markers — IgG, albumin, and fibrinogen — were detected and confined to the same white matter areas, supporting a focal vascular permeability signal accompanying tissue injury.
The pattern of MRI and histology indicates ischemic white matter degeneration rather than a diffuse inflammatory process. The study team observed temporal lesion expansion over a narrow post-operative window, and behavioral testing revealed functional impact in affected animals. The source did not provide long-term recovery trajectories beyond the reported 7-to-9-week window.
To probe mechanism, the authors tested the effects of angiotensin II (Ang II) on brain endothelial cells. Data indicated that Ang II impaired barrier function, measured by transendothelial electrical resistance assays, and increased reactive oxygen species (ROS) production. Those effects were mediated through the Ang II type 1 receptor (AT1R), according to the reported assays. The study team linked endothelial barrier compromise and oxidative stress to the focal BBB leakage seen in vivo, providing a mechanistic bridge between renovascular systemic pathology and local white matter injury.
The cell-based assays focused on barrier function and ROS generation; the source did not report additional downstream signaling intermediates or a full dose–response series for Ang II in the endothelial experiments.
The investigators administered losartan intracerebroventricularly to block brain AT1R while avoiding systemic blood pressure reduction. The study team observed attenuation of white matter pathology in treated RVH rats: MRI lesion expansion was reduced and histologic markers of demyelination and oligodendrocyte loss improved. Behavioral outcomes also improved in the intracerebroventricular losartan group, even though systemic arterial pressure remained comparably elevated to untreated RVH animals.
This experiment isolates brain AT1R signaling as a blood pressure–independent contributor to ischemic white matter damage in the RVH model. The authors did not report the specific intracerebroventricular losartan dosing regimen, infusion rate, or cerebrospinal fluid concentration in the source material, so replication would require contact with the corresponding authors for those procedural details.
The preclinical findings were compared with human data drawn from multiple cohorts. In the reported dataset, patients with renal artery stenosis had higher total WMH volumes than those without (10.52 versus 6.52 mL; P = 0.035). The study team also examined WMH progression across antihypertensive drug classes in CHALLENGE (Korea), MSS2 (UK), LBC1936 (UK), and SPRINT-MIND-MRI (US).
In those cohort analyses, angiotensin receptor blocker (ARB) use associated with the slowest tertile of annual WMH progression in the Korean CHALLENGE cohort (OR 2.57; 95% CI, 1.20–5.61). ARB use was also associated with reduced progression among White participants in SPRINT-MIND-MRI (OR 3.52; 95% CI, 1.05–12.29). The authors note that cohort data were drawn from diverse geographic and demographic sources; they reported data availability pathways (for example, SPRINT-MIND-MRI data via NHLBI BioLINCC) and that some cohort-level data require contact with original investigators.
These clinical associations are consistent with the experimental result that brain AT1R signaling can drive white matter injury independently of systemic blood pressure control. The observational nature of cohort analyses, however, precludes causal inference without interventional data targeting central AT1R signaling directly in humans.
The authors declared that data supporting their findings are available upon reasonable request and noted cohort-specific data access points. The source did not provide intracerebroventricular losartan dosing details, infusion parameters, or cerebrospinal fluid pharmacokinetics in the manuscript, and it did not report patient-level antihypertensive exposure timelines beyond class-level associations in cohorts. The study team documented ethical approvals for animal and human components but did not include long-term follow-up beyond the described experimental window for RVH animals.
These omissions constrain direct experimental replication and limit immediate clinical translation until dosing and central pharmacology are clarified. Next steps reported by the authors consist of data-sharing pathways and cohort links; the manuscript itself did not list specific planned clinical trials or regulatory milestones.